Plasma cathepsin D levels were lower in individuals with amyloid plaques in the brain compared to controls, and a logistic regression model indicates a high efficacy of plasma cathepsin D as a diagnostic biomarker for AD [70]. The gene discussed is CTSD; the disease is Alzheimer disease.